USA flag logo/image

An Official Website of the United States Government

Fluorogenic Assays for Measuring the Activity of Ceramidase and Sphingomyelinase

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
89195
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
GM084502
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ECHELON BIOSCIENCES, INC.
675 ARAPEEN DRIVE, SUITE 302 SALT LAKE CITY, UT 84108-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Fluorogenic Assays for Measuring the Activity of Ceramidase and Sphingomyelinase
Agency: HHS
Contract: 1R43GM084502-01
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Sphingolipids are a class of lipids that have important roles as structural components of cell membranes yet are also key signaling molecules involved in numerous cellular processes such as apoptosis, cell survival, dif ferentiation, motility, and growth. The levels of the various sphingolipids are kept in balance by metabolizing enzymes and disruptions by abnormal levels of these enzymes are known to occur in diseases such as cancer, diabetes, arthersclerosis, and autoim mune disorders. In this application, fluorogenic assays for two important sphingolipid metabolizing enzymes, ceramidase and sphingomyelinase, will be developed. The fluorescence dequenching assays utilize internally quenched fluorescent substrates which, w hen hydrolyzed by the enzymes, fluoresce due to the quencher no longer being in close proximity to the fluor. Labeled analogs of ceramide and sphingomyelin will be synthesized, evaluated as substrates with their respective enzymes, and the assay conditions will be optimized. These assays can be employed to further basic research and be adapted to high throughput screening for therapeutic compounds. PUBLIC HEALTH RELEVANCE: The overall goal of this project is to develop assays for two important lipid metabolizing enzymes: ceramidase and sphingomyelinase. These assays will help to further basic research in this growing field and potentially be used for developing new drugs for diseases such as cancer, diabetes, and Alzheimer's disease.

Principal Investigator:

Business Contact:


ksauder@echelon-inc.com
Small Business Information at Submission:

ECHELON BIOSCIENCES, INC.
675 ARAPEEN DRIVE, SUITE 302 SALT LAKE CITY, UT 84108

EIN/Tax ID: 841417180
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No